HCV-1: DCV+SOF salvage therapy effective in decompensated cirrhosis

Access to the full content of this site is available only to registered healthcare professionals. Register to read more


  • A 24-wk regimen of daclatasvir (DCV; Daklinza) + sofosbuvir (SOF; Sovaldi) with ribavirin (RBV) achieves a high HCV-1 clearance rate in treatment-experienced patients with decompensated cirrhosis.

Why this matters

  • This population is typically excluded from clinical trials.